17 jul: BASE METALS HIGHLIGHTS: Top Stories of the Day
17 jul: UPDATE: CSX 2nd-Quarter Profit Up 1.2% as Intermodal, Automotive ..
17-07-2012 23:37:00

GlaxoSmithKline and Amicus Expand Drug Collaboration

Relateret indhold

By Ben Fox Rubin

Amicus Therapeutics Inc. (FOLD) and GlaxoSmithKline PLC (GSK, GSK.LN) said they are expanding their collaboration to develop a treatment for Fabry disease, with Glaxo agreeing to buy a larger stake in the smaller pharmaceutical company.

The deal includes co-development of all current and future formulations of migalastat HCl for Fabry disease, which is a lipid storage disorder, as well as a commercialization arrangement for all future Fabry products. Amicus will have commercial rights in the U.S., while Glaxo will have rights for the rest of the world.

Glaxo also agreed to buy $18.6 million in Amicus's common stock at $6.30 a share, a 4.7% premium over Tuesday's close, raising its ownership in the company to 20%.

"Through our expanded agreement, GSK is increasing its investment in the Fabry development program and Amicus is transforming into a commercial-stage biopharmaceutical company within the U.S.," said Amicus Chief Executive John Crowley.

Amicus makes oral therapeutics known as pharmacological chaperones to treat a range of human genetic diseases.

Its shares closed Tuesday at $6.02, while Glaxo's closed at $45.44. Neither were active after hours.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 17, 2012 17:37 ET (21:37 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Mærsk: 54 fyringer i amerikansk Oil-sparerunde

21-08-2014 15:08:28
Maersk Oil, Mærsk-koncernens olie- og gasdivision, skærer ned på kontoret i Houston i USA og reducerer lønningslisten med 54 ansatte. Samtidig flyttes otte ansa..

Europa/aktier: Flest positive vinde på kontinentet

21-08-2014 13:16:55
Der er mestendels positiv stemning på aktiemarkederne i Europa torsdag, trods at formiddagens nøgletal fra eurozonen var til den skuffende side.Ved 13-tiden lig..

Vestas/Barclays: Flere spørgsmål end svar efter Q2

21-08-2014 11:24:24
14 gange afviste Vestas-ledelsen at besvare spørgsmål fra analytikere på onsdagens telekonference, og det får analytikerne i Barclays til at gentage sine forbeh..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/Barclays: Flere spørgsmål end svar efter Q2
2
Vestas henter erstatningsprojekt for kuldsejlet Mareña-park
3
Aktier/tendens: Travl regnskabsdag ventes at præge markedet
4
Torsdagens aktier: Vestas og ISS hev C20 ned på regnskabsdag
5
Vestjysk Bank Q2: Regnskabstal vidner om markant vending

Relaterede aktiekurser

Amicus Therapeutics Inc 5,41 -1,6% Fald i aktiekurs
GlaxoSmithKline PLC 47,70 -0,2% Fald i aktiekurs
GlaxoSmithKline PLC 1.434,50 0,0% Aktiekurs uændret
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. august 2014 05:57:14
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140819.1 - EUROWEB7 - 2014-08-22 05:57:14 - 2014-08-22 05:57:14 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x